Animal studies: adrenal gland and bladder effects
A seven-year feeding study in female beagle dogs at high dietary doses found moderate to marked atrophy of the outer layer of the adrenal gland (the zone glomerulosa) in all test animals, along with adrenal adenomas at the highest dose. The same study found haemorrhagic streaks and blood-filled projections in the urinary bladder of all surviving animals after six months. These were the findings that informed regulators' decisions not to establish a safe daily intake.
Seven-year dog feeding study found marked atrophy of the adrenal gland's zone glomerulosa in all animals at both dose levels (10,000 and 20,000 ppm in diet), with adrenal cortical adenomas at the highest dose.
1977AnimalJECFA Monograph No. 445, WHO Food Additives Series 12
Haemorrhagic streaks and blood-filled mucosal projections in the urinary bladder of all test animals surviving more than six months at both dose levels in the dog feeding study.
1977AnimalJECFA Monograph No. 445, WHO Food Additives Series 12
IARC carcinogenicity evaluation
IARC evaluated Ponceau SX in 1975 and again in 1987. Animal studies by oral administration in mice, rats and dogs, and by injection in mice and rats, did not show evidence of a carcinogenic effect. IARC placed it in Group 3, meaning it cannot be classified as to its carcinogenicity to humans, due to inadequate evidence in both animals and humans.
Oral studies in mice, rats and dogs did not indicate a carcinogenic effect. IARC classified Ponceau SX as Group 3: not classifiable as to carcinogenicity to humans. The Volume 8 (1975) page on inchem.org explicitly records the subsequent evaluation as 'Suppl. 7 (1987) (p. 70: Group 3)'.
1987AnimalIARC Monographs Volume 8 (1975) and Supplement 7 (1987), p. 70; inchem.org IARC Vol. 8 Ponceau SX page
JECFA: no safe intake level established
The Joint FAO/WHO Expert Committee on Food Additives evaluated Ponceau SX across multiple meetings from 1959 to 1977 and each time postponed its decision, declining to set an acceptable daily intake. The committee's specifications for the dye were formally withdrawn in 1984, signalling that no basis for a safe level in food had been found.
JECFA evaluated Ponceau SX in 1959, 1964 and 1977 and each time returned a postponed decision, never establishing an acceptable daily intake. Specifications were withdrawn in 1984.
1984Regulatory reviewJECFA Evaluations database (inchem.org), Scarlet GN entry
Azo dye metabolism: aromatic amine release
Like other azo dyes, Ponceau SX can be reduced by gut bacteria to produce aromatic amine compounds. The JECFA monograph identified metabolites including aminohydroxynaphthalenesulfonic acid derivatives. Some aromatic amines produced by azo dye breakdown are known or suspected to be toxic, though whether the specific metabolites from Ponceau SX pose a meaningful risk at former food-use levels was not formally resolved.
Ponceau SX undergoes bacterial reduction in the intestine, producing metabolites including amino-hydroxynaphthalene derivatives, as identified in the JECFA toxicological monograph.
1977LabJECFA Monograph No. 445, WHO Food Additives Series 12
Gut bacteria with azoreductase activity are widespread in the human intestinal microbiome and cleave the azo bond of food dyes, producing aromatic amine metabolites.
1992LabGingell et al., The reduction of azo dyes by the intestinal microflora, Xenobiotica